- If you are wondering whether Ultragenyx Pharmaceutical at US$23.15 is a bargain or a value trap, the key is understanding what the current price actually implies about the business.
- The stock has returned 8.1% over the last week and 2.4% over the last month, but is still showing a 1.9% decline year to date and a 31.7% decline over the last year, with even deeper 3 year and 5 year returns of 38.3% and 78.6% respectively.
- These moves sit against a backdrop of ongoing interest in rare disease treatments and the broader biotech sector, where sentiment can shift quickly as trial results, regulatory updates or partnership news emerge. Even without a single headline driving the latest 8.1% weekly gain, price action like this often reflects changing market views on risk and potential reward for companies like Ultragenyx Pharmaceutical.
- Ultragenyx Pharmaceutical currently has a valuation score of 4 out of 6, which suggests some areas look attractive while others warrant closer inspection. The rest of this article will walk through the main valuation methods investors typically use and then finish with a more holistic way to think about what the stock might be worth.
Approach 1: Ultragenyx Pharmaceutical Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting them back to today’s value using a required rate of return.
For Ultragenyx Pharmaceutical, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve months free cash flow (FCF) is a loss of about $501.5 million. Analysts and model assumptions then project FCF turning positive, reaching $102.5 million in 2026 and $938 million in 2030, with further years extrapolated by Simply Wall St rather than based on direct analyst estimates.
When all those projected cash flows are discounted back, the estimated intrinsic value comes out at about $257.43 per share. Compared with the recent share price of about $23.15, the DCF output indicates the stock is around 91.0% undervalued on this set of assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Ultragenyx Pharmaceutical is undervalued by 91.0%. Track this in your watchlist or portfolio, or discover 64 more high quality undervalued stocks.
Approach 2: Ultragenyx Pharmaceutical Price vs Sales
For companies that are not yet profitable, the P/S ratio is often more useful than P/E or P/B because it compares the share price with revenue rather than earnings or accounting book value. It gives you a quick sense of how much investors are paying for each dollar of current sales.
Growth expectations and risk still matter a lot. Higher expected revenue growth and lower perceived risk usually justify a higher “normal” P/S multiple, while slower growth or higher uncertainty generally point to a lower multiple being more appropriate.
Ultragenyx Pharmaceutical currently trades at a P/S of 3.38x. That is below the Biotechs industry average P/S of 11.38x and also below the peer group average of 7.97x. Simply Wall St’s Fair Ratio for Ultragenyx Pharmaceutical is 2.06x, which is its proprietary estimate of what the P/S should be after considering factors such as growth prospects, profit margins, industry, market cap and specific risks.
This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific qualities rather than assuming one size fits all. With the current 3.38x P/S sitting above the 2.06x Fair Ratio, the shares appear overvalued on this metric.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your Ultragenyx Pharmaceutical Narrative
Earlier the article mentioned that there is an even better way to think about valuation. On Simply Wall St this is captured in Narratives, where you choose or create a clear story for Ultragenyx Pharmaceutical, link that story to specific assumptions for future revenue, earnings and margins, and the platform then turns it into a Fair Value that you can compare with today’s price. This allows you to decide whether the stock looks expensive or cheap on your terms, with the Narrative updating automatically when fresh information such as earnings or trial news is added.
On the Community page, Narratives are easy to use because they sit on a simple story-plus-numbers framework. You can see, for example, one Ultragenyx Pharmaceutical Narrative that leans on an optimistic view with a Fair Value around US$84 based on faster growth and higher margins, alongside a more cautious Narrative with a Fair Value near US$25 that builds in slower growth, lower margins and higher risk. You can then decide which version feels closer to your own view or adjust the inputs to build something in between.
Do you think there's more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com